Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma

IntroductionCurrent prognostic blood-based biomarkers for pancreatic adenocarcinoma (PDAC) are limited. Recently, promoter hypermethylation of SFRP1 (phSFRP1) has been linked to poor prognosis in patients with gemcitabine-treated stage IV PDAC. This study explores the effects of phSFRP1 in patients...

Full description

Bibliographic Details
Main Authors: Benjamin Emil Stubbe, Anders Christian Larsen, Poul Henning Madsen, Henrik Bygum Krarup, Inge Søkilde Pedersen, Søren Lundbye-Christensen, Carsten Palnæs Hansen, Jane Preuss Hasselby, Astrid Zedlitz Johansen, Ole Thorlacius-Ussing, Julia Sidenius Johansen, Stine Dam Henriksen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
biomarker
pancreatic cancer
survival
epigenetic
DNA methylation
personalized therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1211292/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1211292/full

Similar Items